211 related articles for article (PubMed ID: 14962233)
1. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
2. rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H
Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
Prutchi-Sagiv S; Golishevsky N; Oster HS; Katz O; Cohen A; Naparstek E; Neumann D; Mittelman M
Br J Haematol; 2006 Dec; 135(5):660-72. PubMed ID: 17107348
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.
Mittelman M; Neumann D; Peled A; Kanter P; Haran-Ghera N
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5181-6. PubMed ID: 11309490
[TBL] [Abstract][Full Text] [Related]
5. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin enhances immune responses in mice.
Katz O; Gil L; Lifshitz L; Prutchi-Sagiv S; Gassmann M; Mittelman M; Neumann D
Eur J Immunol; 2007 Jun; 37(6):1584-93. PubMed ID: 17458859
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
9. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
Holley JL; Nolan TA; Piraino B
Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
12. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
13. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma.
Dammacco F; Luccarelli G; Prete M; Silvestris F
Rev Clin Exp Hematol; 2002; Suppl 1():32-8. PubMed ID: 12735213
[TBL] [Abstract][Full Text] [Related]
14. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
Palumbo C; Battisti S; Carbone D; Albonici L; Alimandi M; Bei R; Modesti A
Cancer Chemother Pharmacol; 2008 Apr; 61(5):893-901. PubMed ID: 17922127
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysed patients.
Ruedin P; Pechère Bertschi A; Chapuis B; Benedet P; Leski M
Nephrol Dial Transplant; 1993; 8(4):315-8. PubMed ID: 8390005
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.
Hedley BD; Chu JE; Ormond DG; Beausoleil MS; Boasie A; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(19):6151-62. PubMed ID: 21856770
[TBL] [Abstract][Full Text] [Related]
17. Use of erythropoietin in patients with multiple myeloma.
Egerer G; Harter C; Karthaus M; Ho AD; Goldschmidt H
Onkologie; 2003 Feb; 26(1):80-4. PubMed ID: 12624523
[TBL] [Abstract][Full Text] [Related]
18. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.
Ludwig H; Pecherstorfer M; Leitgeb C; Fritz E
Stem Cells; 1993 Sep; 11(5):348-55. PubMed ID: 8241947
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
